[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-171932-105":53,"doc-detail-171932-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","gcp-essential-documents-and-the-regulatory-binder-a-toolkit","GCP Essential Documents and the Regulatory Binder - A Toolkit","","GCP regulated research must follow Good Clinical Practice, and Section 8 specifies the “Essential Documents” investigators create and maintain for each GCP-covered study. These documents are commonly organized as a “Regulatory Binder,” reviewed during FDA inspections, routine monitoring, and in line with the study’s monitoring plan. The toolkit recommends a stepwise process: review required documents by trial stage, choose recordkeeping formats, assign responsibilities and training, complete a checklist with location and ownership, and ensure accessibility to monitors, IRB, and regulators, including defined retention periods.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/gcp-essential-documents-and-the-regulatory-binder-a-toolkit/171932/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/gcp-essential-documents-and-the-regulatory-binder-a-toolkit/171932.png","ImageObject",442,249,{"name":88,"@type":89},"Ava Thompson","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-28","2026-09-01",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",8,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What are “Essential Documents” under GCP, and who is responsible for them?","Question",{"text":109,"@type":110},"GCP Section 8 requires investigators to create and maintain the Essential Documents for a GCP-covered study. Each protocol or study should maintain these documents separately.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"How should investigators organize the Essential Documents for a GCP-covered study?",{"text":114,"@type":110},"The collection of Essential Documents is commonly referred to as the “Regulatory Binder.” Investigators can choose an appropriate method and format (hard copy, electronic, or both) rather than being limited to a physical binder.",{"name":116,"@type":107,"acceptedAnswer":117},"What is the purpose of the “Checklist of GCP Essential Documents”?",{"text":118,"@type":110},"At each study stage, investigators complete the checklist to record each document, its location, its format, and the responsible person.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},171932,1788287886,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":8,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":126,"read_time":79},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","GCP Essential Documents and the Regulatory Binder:  A Toolkit\nFDA regulated research is required to conform to standards of \u0013 HYPERLINK \"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf\" \u0014Good Clinical Practice (GCP)\u0015.  Section 8 of the GCP guidelines outlines the “Essential Documents” that investigators are responsible for creating and maintaining.  The collection of these Essential Documents for a GCP-covered study are commonly referred to as the “Regulatory Binder.”  Although the name implies a physical binder with hard-copy documents, investigators are free to determine the most appropriate method and format for fulfilling these recordkeeping requirements.  In the event of an FDA inspection or audit, the FDA will review the Regulatory Binder.  In addition, the Regulatory Binder and all associated essential documents are to be reviewed during routine monitoring of the study in accordance with its prescribed monitoring plan.\nTo assist sponsor-investigators in complying with the GCP requirements for Essential Documents, the following process, tools, and templates are recommended:\nStep 1: Review \u0013 HYPERLINK \"http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf\" \u0014GCP\u0015’s list of \u0013 HYPERLINK \"http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073122.pdf\" \u0014Essential Documents\u0015 (starts page 50).  They are broken down into 3 categories:  “Before the Clinical Phase of the Trial Commences,” “During the Clinical Conduct of the Trial,” and “After Completion or Termination of the Trial.”  The Essential Documents should be maintained separately for each separate protocol/study.\nStep 2: Evaluate and determine your preferred method for fulfilling each recordkeeping requirement.  You may utilize hard copies or electronic format, or a combination of both.  Please see the remaining pages of this toolkit document for a collection of recordkeeping templates and tools for your consideration.\nStep 3: Determine responsibility for creation and maintenance of each Essential Document.  Communicate this delegation of authority to each responsible person, and train them on your preferred methods.  As Principal Investigator, you have ultimate responsibility over the proper maintenance of the Regulatory Binder.\nStep 4: At each stage of the study, complete the “Checklist of GCP Essential Documents” to record each document, its location, format, and responsible person.\u000b\u000bStep 5: Ensure that the Regulatory Binder is part of your routine self-monitoring, and that the records are made accessible to any internal or external monitor, University administrators, the IRB, and any applicable regulatory agency.\nStep 6: Record Retention - study records and essential documents must be retained for the following time period (whichever is longest):\n2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated, or\n3 years after completion/closure of the protocol, or\nRetention period required by specific funding agency.\nTemplates and Tools for Essential Documents / Regulatory Binder\nBefore the Clinical Phase of the Trial Commences\nDuring this planning stage the following documents should be generated and should be on file before the trial formally starts.  Guidance: \u0013 HYPERLINK \"https://www.nidcr.nih.gov/research/toolkit/\" \\l \"startup\" \u0014https://www.nidcr.nih.gov/research/toolkit/#startup\u0015\nDuring the Clinical Conduct of the Trial\nIn addition to having on file the above documents, the following should be added to the files during the trial as evidence that all new relevant information is documented as it becomes available.  Guidance: \u0013 HYPERLINK \"https://www.nidcr.nih.gov/research/toolkit/\" \\l \"during\" \u0014https://www.nidcr.nih.gov/research/toolkit/#during\u0015\nAfter Completion or Termination of the Trial\nAfter completion or termination of the trial, all of the documents identified in sections 1 and 2 (listed above) ","cbCaiuX40KD4DYCU","https://ap.wps.com/l/cbCaiuX40KD4DYCU","docx",43341,"English","# Introduction\n## Regulatory Binder concept and review\n# Step-by-step process\n## Review essential documents by trial stage\n## Choose recordkeeping method\n## Assign responsibilities and training\n## Complete the GCP checklist\n## Self-monitoring and access for oversight\n## Record retention requirements\n# Document stages\n## Before the clinical phase begins\n## During the clinical conduct\n## After completion or termination\n# Additional resources","[{\"question\":\"What are “Essential Documents” under GCP, and who is responsible for them?\",\"answer\":\"GCP Section 8 requires investigators to create and maintain the Essential Documents for a GCP-covered study. Each protocol or study should maintain these documents separately.\"},{\"question\":\"How should investigators organize the Essential Documents for a GCP-covered study?\",\"answer\":\"The collection of Essential Documents is commonly referred to as the “Regulatory Binder.” Investigators can choose an appropriate method and format (hard copy, electronic, or both) rather than being limited to a physical binder.\"},{\"question\":\"What is the purpose of the “Checklist of GCP Essential Documents”?\",\"answer\":\"At each study stage, investigators complete the checklist to record each document, its location, its format, and the responsible person.\"}]","GCP Essential Documents and the Regulatory Binder - A Toolkit | DOCX"]